SV Life Sciences maintains ophthalmology focus by backing Imagen Biotech
This article was originally published in Scrip
SV Life Sciences reinforced its interest in backing biotechs focusing on ophthalmology by participating in the $40 million series A round closed by Imagen Biotech, a New York-based start-up. The financing round represents the fifth investment in an ophthalmology company this year, and the ninth one in the past three years. SV Life Sciences was joined by Novo Ventures and Fidelity Biosciences.